Results 11 to 20 of about 252,964 (178)

MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. [PDF]

PLoS ONE, 2017
BACKGROUND:In 2013, approximately 480,000 people developed active multidrug-resistant tuberculosis (MDR-TB), while only 97,000 started MDR-TB treatment.
Emily A Kendall, Andrew S Azman, Frank G Cobelens, David W Dowdy   +3 more
doaj   +2 more sources

MDR-TB updated data.

, 2023
BackgroundMultidrug-resistant tuberculosis (MDR-TB) remains a public health emergency and a threat globally. Although increasing MDR-TB cases have been recently reported in Somalia, limited information is known.
Celso José Bruno de Oliveira (11497468), Abdinasir Yusuf Osman (16949157), Shu-Hua Wang (4726611), Omer Abdikarin Ali (16949139), Mustapha Goni Abatcha (16949145), Mohamed Abdelrahman Mohamed (16949136), Abdifatah Ahmed Dirie (16949154), Aamir Muse Osman (16949142), Rafael F. C. Vieira (5624948), Ali Mohamed Ali (16949151), Abdirahman Abdirizak Ahmed (16949148)   +10 more
core   +1 more source

Multidrug-resistant tuberculosis surveillance and cascade of care in Madagascar: a five-year (2012–2017) retrospective study

BMC Medicine, 2020
Background In Madagascar, the multidrug-resistant tuberculosis (MDR-TB) surveillance programme was launched in late 2012 wherein previously treated TB cases and symptomatic MDR-TB contacts (hereafter called presumptive MDR-TB cases) undergo drug ...
Astrid M. Knoblauch, Simon Grandjean Lapierre, Daniella Randriamanana, Mamy Serge Raherison, Andrianantenaina Rakotoson, Bienvenue Solofomandimby Raholijaona, Masiarivony Ravaoarimanga, Pascaline Elisabeth Ravololonandriana, Marie-Sylvianne Rabodoarivelo, Orelys Ratsirahonana, Fanjasoa Rakotomanana, Turibio Razafindranaivo, Voahangy Rasolofo, Niaina Rakotosamimanana   +13 more
doaj   +1 more source

Self-reported risks for multiple-drug resistance among new tuberculosis cases: implications for drug susceptibility screening and treatment. [PDF]

PLoS ONE, 2011
BACKGROUND: Multiple drug-resistance in new tuberculosis (TB) cases accounts for the majority of all multiple drug-resistant TB (MDR-TB) worldwide. Effective control requires determining which new TB patients should be tested for MDR disease, yet the ...
Timothy F Brewer, Howard W Choi, Carlos Seas, Fiorella Krapp, Carlos Zamudio, Lena Shah, Antonio Ciampi, S Jody Heymann, Eduardo Gotuzzo   +8 more
doaj   +1 more source

Rifampicin resistance in new bacteriologically confirmed pulmonary tuberculosis patients in Cameroon: a cross-sectional survey

BMC Research Notes, 2018
Objective In Cameroon, tuberculosis (TB) cases are diagnosed and treated within a nationwide network of 248 diagnostic and treatment centres. In 2016, the centers notified a total of 175 multidrug-resistant (MDR-)TB cases, most of them retreatment cases.
J. Noeske, A. Nana Yakam, J. L. Abena Foe, D. Nguafack, C. Kuaban   +4 more
doaj   +1 more source

Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India. [PDF]

, 2012
Significant adverse events (AE) have been reported in patients receiving medications for multidrug- and extensively-drug-resistant tuberculosis (MDR-TB & XDR-TB).
Varghese, B, Tony Reid, Paryani Roma, Mansoor Homa, Isaakidis, P, Paryani, Roma, Isaakidis, Petros, Cox, Helen S., Udwadia, Zarir, Sotgiu, Giovanni, Khan Samsuddin, Ladomirska, J, Cox, H S, Reid, Tony, Giovanni Battista Migliori, Ladomirska Joanna, Paryani, R, Da Silva Esdras, Udwadia Zarir, Petros Isaakidis, Peter Saranchuk, Joanna Ladomirska, Zarir Udwadia, Bhanumati Varghese, Roma Paryani, Ladomirska, Joanna, Varghese, Bhanumati, Sotgiu Giovanni, Khan, S, Migliori, Giovanni Battista, Isaakidis Petros, Saranchuk, Peter, Da Silva, Esdras, Mansoor, H, Homa Mansoor, Khan, Samsuddin, Saranchuk Peter, Esdras Da Silva, Migliori, G B, Migliori Giovanni Battista, Mansoor, Homa, Reid Tony, Varghese Bhanumati, Cox Helen S., Giovanni Sotgiu, Saranchuk, P, Da Silva, E, Udwadia, Z, Reid, T, Helen S Cox, Sotgiu, G, Samsuddin Khan   +51 more
core   +1 more source

82125 Multiple epidemics of multidrug-resistant tuberculosis revealed by spatial disease mapping and whole-genome sequencing analysis in urban China

Journal of Clinical and Translational Science, 2021
IMPACT: Our study will integrate state-of-the-art methods in pathogen genomics, epidemiology, and geospatial analysis to identify both host- and pathogen-factors driving the MDR-TB transmission and the study outcome can inform the design of targeted ...
Chongguang Yang, Yangyi Zhang, Yuan Jiang, Zheyuan Wu, Xin Shen, Joshua L. Warren, Ted Cohen   +6 more
doaj   +1 more source

Comparison of Line Probe Assay (LPA) and Mycobacterium Growth Indicator Tubes (MGIT) Assay for Second-line TB Drug Susceptibility Testing [PDF]

, 2021
BACKGROUND: Tuberculosis (TB) infection is one of the most prominent health issues in the world, including in Indonesia. TB is evolving into multidrug-resistant tuberculosis (MDR-TB) and requiring second-line TB drugs. Mycobacterium growth indicator tube
Choerunisa, Towifah Fauziah, Rostini, Tiene, Lismayanti, Leni, Bayusantika, Ryan, Parwati, Ida   +4 more
core   +1 more source

Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study

Infectious Diseases of Poverty, 2020
Background China incurs an extremely low treatment coverage of multidrug-resistant tuberculosis (MDR-TB). This study aimed to understand the experience of MDR-TB patients on quality of health care, and the clinical impact through an up to six-year follow-
Xu-Bin Zheng, Vinod K. Diwan, Qi Zhao, Yi Hu, Judith Bruchfeld, Wei-Li Jiang, Sven Hoffner, Biao Xu   +7 more
doaj   +1 more source

Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres

BMC Infectious Diseases, 2019
Background The increased incidence of drug-resistant TB is a major challenge for effective TB control. Limited therapeutic options and poor treatment outcomes of DR-TB may increase drug-resistance rates.
Niccolò Riccardi, Riccardo Alagna, Laura Saderi, Maurizio Ferrarese, Paola Castellotti, Ester Mazzola, Saverio De Lorenzo, Pietro Viggiani, Zarir Udwadia, Giorgio Besozzi, Daniela Cirillo, Giovanni Sotgiu, Luigi Codecasa, for StopTB Italia Onlus Group   +13 more
doaj   +1 more source